Key Highlights

  • The company expects the FDA’s written responses to its pre-IND meeting request by mid-November 2026.
  • Vectus held $410,000 in cash at 30 September, enough for about 1.33 quarters before an R&D tax refund received in October.
  • VB0004 has completed a Phase Ia study in healthy volunteers, which showed a favourable safety and pharmacokinetic profile.
  • Professor Tamera Corte was appointed as Chief Clinical Advisor on 9 November 2026 to support a planned adaptive Phase Ib/IIa trial.

Vectus Biosystems (ASX:VBS) is preparing to take its lead drug candidate, VB0004, into further human trials for idiopathic pulmonary fibrosis (IPF), and the next step it has flagged is written feedback from the US Food and Drug Administration. The company said in its September quarter report that it expects the FDA's responses to its pre-Investigational New Drug (pre-IND) meeting request by mid-November 2026.

That regulatory step sits against a tight balance sheet. According to its Appendix 4C released on 29 October 2026, Vectus held $410,000 in cash at 30 September, enough for about 1.33 quarters at the latest rate of spending, before counting an R&D tax refund received in October.

What Vectus does

Vectus is a Sydney-based, clinical-stage biotechnology company developing treatments for fibrotic diseases, in which scar tissue builds up in organs. VB0004 is an oral compound that the company describes as first in class. It has completed a Phase Ia study in healthy volunteers, which the company says showed a favourable safety and pharmacokinetic profile. That is early-stage safety data, not evidence of effectiveness in patients, and the drug is not approved anywhere.

The company also has earlier-stage compounds aimed at heart, kidney and liver fibrosis.

Recent developments

On 30 September 2026, Vectus said the FDA had granted its request for a pre-IND Type B meeting on the proposed VB0004 programme in IPF, to be conducted through written responses. In July it engaged Cardinal Health Regulatory Services as its US regulatory agent to handle FDA submissions, including a planned Orphan Drug designation request and an eventual IND application.

On 9 November 2026, Vectus appointed Professor Tamera Corte, Director of Interstitial Lung Disease at Royal Prince Alfred Hospital, as Chief Clinical Advisor. The company said the appointment supports progress towards an adaptive Phase Ib/IIa trial in IPF. No trial start date has been announced.

Cash, funding and dilution

In the September quarter, net operating cash outflow was $309,000 and no Equity was raised. A $450,000 Loan Facility was fully drawn. The company received a $208,000 R&D tax refund in October. Related-party payments of $75,000 covered the chief executive's salary and corporate services fees.

Vectus says spending has fallen sharply since the Phase Ia study ended, with fewer staff and consultants, the chief executive also acting as chief technology officer, and cheaper premises. It says it is pursuing licensing deals and may sell some of its shares in XORTX Therapeutics. Those shares were received as consideration when Vectus sold its VB4-P5 kidney fibrosis compound to the Nasdaq-listed company, in a deal that closed on 14 April 2026.

In May 2026, Vectus raised $791,000 through a Placement at $0.10 a share, with one attaching option exercisable at $0.20 for each share. Shareholders approved the Options and a 10% placement facility at the Annual General Meeting on 28 October. The preliminary final report showed a profit of $1.56 million for FY26, driven by Revenue of $2.77 million, while the operating cash outflow for the year was $573,395. That suggests much of the reported revenue was non-cash, consistent with the XORTX share consideration.

Risks

The main risks are funding and regulatory. With little more than a quarter of cash, Vectus is likely to need new Capital or a licensing payment to run a Phase Ib/IIa trial, which could dilute shareholders.